"Over the past 11 years of working in China, I have deeply felt the speed of China's transformation. In 2011, the registration of new drugs in China was relatively slow for the medical industry. In recent years, thanks to the reform of the government's innovation policy, the registration speed of innovative drugs in China has basically kept pace with that of the United States and Europe." Peng Zhenke, president of Pfizer Global Biopharmaceutical Business Group in China, pointed out that. The opening of the 5th China Mobile Expo is just around the corner. It is reported that Pfizer will display nearly 20 breakthrough and innovative products and medical solutions at this China Mobile Expo, covering five major therapeutic fields: tumor, vaccine, anti infection, inflammation and immunity, and rare diseases. Among them, the combination packaging of COVID-19 therapeutic drug Nematovir Tablets/Ritonavir Tablets (namely, PAXLOVID?), And Rimegepant, the world's first CGRP receptor antagonist with rapidly dissolving orally disintegrating tablets, which is also the only oral CGRP receptor antagonist approved for the treatment and prevention of migraine. "In recent years, the State Council and the State Food and Drug Administration have issued a series of policies, regulations and guiding principles related to drug review and approval. They have made many achievements in optimizing the drug review and approval process, encouraging innovation, improving drug quality, and strengthening the full life cycle management of drugs. This has undoubtedly injected long-term confidence rooted in the Chinese market into many foreign enterprises, including Pfizer. For example, in February 2022, thanks to the National Drug Express With the continuous optimization of the rapid review and approval process, Pfizer's COVID-19 oral drug PAXLOVIDTM was approved in an emergency and accelerated manner. It only took more than two months from being approved to being transported to the epidemic prevention front line in China. " Peng Zhenke said. As early as 2020, Pfizer put forward the "two 80%" strategy: by the end of 2022, China will participate in more than 80% of global early and critical clinical research; 80% of the projects were declared at the same time and finally introduced into China. The "two 80%" strategy aims to enable China to deeply participate in Pfizer's global R&D process as soon as possible, especially the early clinical research projects, so that Chinese patients can get the breakthrough innovative treatment that Pfizer leads the world faster. Peng Zhenke particularly stressed that "as of July 2022, there are 104 Pfizer projects under research in the world, which is undoubtedly 104 potential opportunities to change the lives of patients in the world, including Chinese patients. In fact, in 2022 alone, Pfizer has been approved as many as 11 new products, new indications or new dosage forms in China, and we are winning more hope for Chinese patients at the rate of" new "every month." Since entering China for more than 30 years, Pfizer has introduced more than 60 innovative drugs, including original research drugs and vaccines, to China, benefiting tens of millions of Chinese patients. By 2025, Pfizer will also introduce 25 new products, new indications and new dosage forms to China to meet the health needs of Chinese patients throughout their life cycle. Peng Zhenke pointed out that the COVID-19 has brought a huge impact to the world, prompting the pharmaceutical industry to adopt an innovative business model into the market. Pfizer takes four practical actions: first, Pfizer actively promotes digital transformation and provides